Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali.

NCT00652275 is registered in ClinicalTrials.gov with African Malaria Network Trust as lead sponsor.

NCT NCT00652275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00652275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali.
Lead sponsor
African Malaria Network Trust
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2008
Completion date
December 31, 2010
Enrollment
378 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria